Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840545 | 0.95 | GSK3B (0.44) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL1834287 | 0.90 | GSK3B (0.39) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL1835974 | 0.86 | PSEN1 (0.45) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL1834117 | 0.83 | LMNA (0.46) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL1841387 | 0.83 | GSK3B (0.58) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL910170 | 0.82 | GSK3B (0.50) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL910196 | 0.79 | GSK3B (0.46) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL4473538 | 0.77 | PIK3CD (0.45) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL910135 | 0.76 | PIK3CD (0.43) | GSK3BPRKACAROCK2CDC7MAP4K4 | |
| SCHEMBL910226 | 0.75 | GSK3B (0.58) | GSK3BPRKACAROCK2CDC7MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073915-B2 | Substituted pyrimidone derivatives | SANOFI (FR) | 2015-07-07 | — | — | US | claimed |
| JP-2011525906-A | — | — | 2011-09-29 | — | — | JP | claimed |
| US-20110144133-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2321314-A2 | SUBSTITUTED PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | claimed |
| EP-2138493-A1 | Substituted pyrimidone derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2009156861-A2 | SUBSTITUTED PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | claimed |
| EP-2321314-B1 | SUBSTITUTED PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-9073915-B2 | Substituted pyrimidone derivatives | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20110144133-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2138493-A1 | Substituted pyrimidone derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156861-A2 | SUBSTITUTED PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144133-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVES | DHFR, TYMP, DPYD | GSK3B 4094/4885PRKACA 2860/4885ROCK2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.